- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 40/30 - Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
Patent holdings for IPC class A61K 40/30
Total number of patents in this class: 172
10-year publication summary
|
4
|
10
|
10
|
27
|
18
|
19
|
11
|
4
|
34
|
26
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20590 |
5 |
| The Board of Trustees of the Leland Stanford Junior University | 6615 |
5 |
| The Trustees of the University of Pennsylvania | 4403 |
5 |
| Allogene Therapeutics, Inc. | 162 |
5 |
| Immunitybio, Inc. | 496 |
5 |
| FATE Therapeutics, Inc. | 230 |
4 |
| Baylor College of Medicine | 1000 |
3 |
| King's College London | 555 |
3 |
| Memorial Sloan-Kettering Cancer Center | 2013 |
3 |
| Poseida Therapeutics, Inc. | 170 |
3 |
| Adicet Therapeutics, Inc. | 39 |
3 |
| University of Florida Research Foundation, Inc. | 4159 |
2 |
| Adaptimmune Limited | 163 |
2 |
| Cellectis | 411 |
2 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1010 |
2 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3154 |
2 |
| Kite Pharma, Inc. | 438 |
2 |
| Ludwig Institute for Cancer Research Ltd | 194 |
2 |
| Nantbio, Inc. | 144 |
2 |
| Nkarta, Inc. | 78 |
2 |
| Other owners | 110 |